Judicial Review - judgement expected at 3pm

RNS Number : 1740C

Abingdon Health PLC

07 October 2022

 

Abingdon Health plc

("Abingdon Health" or "the Company")

Judicial Review - judgement expected at 3pm

York, U.K. 7 October 2022:  Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, notes that the judgement in relation to the Judicial Review proceedings initiated by the Good Law Project Limited ("GLP") against the Department of Health and Social Care ("DHSC") is now expected to be handed down at 3pm today. Abingdon Health is an interested party in the case.

Details are provided in section 17.4 of this link:

https://www.gov.uk/government/publications/business-and-property-courts-rolls-building-cause-list/business-and-property-courts-of-england-and-wales-cause-list#technology-and-construction-court-kings-bench-division

A further announcement will be made once the outcome of the Judicial Review is known.

Enquiries

Abingdon Health plc		www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer		Via Walbrook PR
Melanie Ross , Chief Financial Officer
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Nominated Adviser)		Tel: [phone]
Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Phillip Marriage Alice Woodings	Mob: [phone] [phone]

About Abingdon Health plc

Abingdon Health is a world leading  developer and manufacturer of high-quality lateral flow rapid tests  across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx^®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit:  www.abingdonhealth.com

 

END

 

 

MSCBKOBNCBDKNKK